Literature DB >> 8396729

DNA topoisomerase I is involved in both repression and activation of transcription.

A Merino1, K R Madden, W S Lane, J J Champoux, D Reinberg.   

Abstract

Reconstituted transcription reactions containing the seven general transcription factors, in addition to RNA polymerase II, respond poorly to transcriptional activators. Two factors, Dr2 and ACF, necessary for high levels of transcription in response to an activator have been identified. ACF can enhance basal and activated transcription. Dr2 represses basal transcription, but this can be overcome by transcriptional activators or TFIIA. Dr2 is human DNA topoisomerase I. The DNA relaxation activity of topoisomerase I is dispensable for transcriptional repression. The effect of Dr2 is specific for TATA-box-containing promoters and is mediated by the TATA-binding protein.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8396729     DOI： 10.1038/365227a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  121 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  The general transcription factors IIA, IIB, IIF, and IIE are required for RNA polymerase II transcription from the human U1 small nuclear RNA promoter.

Authors:  T C Kuhlman; H Cho; D Reinberg; N Hernandez
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

4.  Disconnecting XRCC1 and DNA ligase III.

Authors:  Sachin Katyal; Peter J McKinnon
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 5.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

6.  Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.

Authors:  Neelima Mondal; Ye Zhang; Zophonias Jonsson; Suman Kumar Dhar; Madhu Kannapiran; Jeffrey D Parvin
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

7.  Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors.

Authors:  Stéphanie Solier; Jennifer Barb; Barry R Zeeberg; Sudhir Varma; Mike C Ryan; Kurt W Kohn; John N Weinstein; Peter J Munson; Yves Pommier
Journal:  Cancer Res       Date:  2010-09-03       Impact factor: 12.701

8.  The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase.

Authors:  S Gangloff; J P McDonald; C Bendixen; L Arthur; R Rothstein
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.

Authors:  M Satoh; A K Ajmani; T Ogasawara; J J Langdon; M Hirakata; J Wang; W H Reeves
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  A cell-specific factor represses stimulation of transcription in vitro by transcriptional enhancer factor 1.

Authors:  S Chaudhary; C Brou; M E Valentin; N Burton; L Tora; P Chambon; I Davidson
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.